Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 16/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937826 | 1.00 | RBP4 (0.51) | RBP4ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL19937827 | 1.00 | RBP4 (0.51) | RBP4ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL19937840 | 0.80 | RBP4 (0.50) | RBP4ALDH1A1 | |
| SCHEMBL19937839 | 0.80 | RBP4 (0.50) | RBP4ALDH1A1 | |
| SCHEMBL27856942 | 0.76 | RBP4 (0.47) | RBP4ALDH1A1 | |
| SCHEMBL3436350 | 0.75 | SLC18A3 (0.54) | ALDH1A1TSHR | |
| SCHEMBL3436349 | 0.75 | SLC18A3 (0.54) | ALDH1A1TSHR | |
| SCHEMBL32679327 | 0.75 | RBP4 (0.60) | RBP4HTR7 | |
| SCHEMBL3436351 | 0.75 | SLC18A3 (0.54) | ALDH1A1TSHR | |
| SCHEMBL2977743 | 0.75 | RBP4 (0.60) | RBP4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | RBP4 4859/4885ALDH1A1 4783/4885TSHR 3612/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | RBP4 4859/4885ALDH1A1 4783/4885TSHR 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.